This site is intended for healthcare professionals

Top line results for AVT 02 shows no difference in switching with Humira.- Alvotech

Read time: 1 mins
Last updated:12th Sep 2021
Published:12th Sep 2021
Alvotech announced top-line results from a randomized study in patients that demonstrate bioequivalence of repeated switches between administration of Humira (adalimumab) and Alvotech’s high-concentration biosimilar candidate, AVT 02 (adalimumab biosimilar) (100 mg/mL) to administration of Humira without switching. Further, no significant differences were observed in clinical efficacy, safety or immunogenicity between the switching cohort and the reference product cohort.
Condition: RA/AnkSpon/Crohns/UC/PsA/Ps
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest